ClinicalTrials.Veeva

Menu

Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery (InfantDex)

A

Athena Zuppa

Status and phase

Completed
Phase 1

Conditions

Tricuspid Atresia
Tetralogy of Fallot
Hypoplastic Left Heart

Treatments

Drug: Dexmedetomidine

Study type

Interventional

Funder types

Other

Identifiers

NCT00573066
2004-5-3770

Details and patient eligibility

About

This study is being conducted to determine what dexmedetomidine does to the body and in turn, what how the body handles the medication. This medication, for the purpose of this trial, is used as a short-term sedative for infants who are immediately post-operative from cardiac surgery and have a breathing tube and are breathing with the assistance of a mechanical ventilator or breathing machine.

Full description

This is a single center, dose escalation study of a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours in infants who are immediately post-operative from cardiac surgery and require tracheal intubation with mechanical ventilation in the post-operative period. Three bolus doses and infusion doses will be administered to a total of 36 evaluable patients.

Enrollment

56 patients

Sex

All

Ages

1 to 24 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients must be greater or equal to one month or less than or equal to 24 months of age.
  • Post operative from cardiac surgery with tracheal intubation/mechanical ventilation in the immediate post-op period.
  • Planned tracheal extubation within 24 hours post-operatively.
  • Adequate renal function(1-12 months old creatinine less than or equal to 0.6mg/dL and >12 months to 24 months creatinine < or= to 1.0mg/dL)
  • Adequate liver function(Total bilirubin < or= 1.5mg/dL and ALT 1-12 months < or = to 165 U/L and > 12 months to 24 months < or = to 90 U/L)
  • Isolated heart surgery
  • Informed consent

Exclusion criteria

  • Patients who have received another investigational drug within the past 30 days.
  • Receiving continuous infusions of muscle relaxants in the postoperative setting.
  • Patients whoo have a positive blood culture without a subsequent negative culture or other evidence of ongoing serious infection.
  • Patients, who, int he opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
  • Patients who show signs or symptoms of elevated intracranial pressure.
  • Post-operative hypotension based on age.
  • Preexisting bradycardia based on age.
  • Heart block
  • Weight < 5kg
  • Patients, who in the opinion of the investigator, are not appropriate candidates for an investigational drug study.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

56 participants in 1 patient group

Dosing level
Experimental group
Description:
A predetermined dose of Dexmedetomidine
Treatment:
Drug: Dexmedetomidine

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems